NCT05955105 - A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

January 25, 2026

Study Completion Date

July 24, 2026

Conditions

Head and Neck CancerCervical CancerEndometrial CancerTriple Negative Breast CancerOvarian CancerSoft Tissue SarcomaMelanomaNasopharyngeal CarcinomaNon Small Cell Lung CancerClassic Hodgkin Lymphoma

Interventions

DRUG

ILB-2109

ILB-2109 tablets will be administered by mouth every day in 21-day cycles

DRUG

Toripalimab

Toripalimab injection will be administered via IV every 21 days.

Trial Locations (1)

Unknown

RECRUITING

Shandong Cancer Hospital, Jinan